IMW 2019 | How will novel agents affect the amyloidosis population?
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, and Raymond Comenzo MD, Tufts University School of Medicine, Boston, MA, discuss how novel agents will affect the standard treatment approach to amyloidosis. They also describe the recent approval of novel stabilizers and silencers, and how they can be implemented in conjunction with liver transplant in the treatment of hereditary amyloidosis. This roundtable was held at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
Get great new content delivered to your inboxSign up